Abstract
No public abstract is available from the verified source records.
Paul Balfanz
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global burden of the key components of cardiovascular-kidney-metabolic syndrome
10.1681/asn.0000000658 · 2025
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
10.1016/s0140-6736(18)32279-7 · 2018
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
10.1016/s0140-6736(23)01301-6 · 2023
Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults
10.1016/s0140-6736(23)02750-2 · 2024
Cardiovascular-kidney-metabolic (CKM) syndrome: a state-of-the-art review
10.1016/j.cpcardiol.2023.102344 · 2024
Prevalence of cardiovascular-kidney-metabolic syndrome stages in US adults, 2011-2020
10.1001/jama.2024.6892 · 2024
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
10.1161/cir.0000000000001184 · 2023
The cardio-renal-metabolic connection: a review of the evidence
10.1186/s12933-023-01937-x · 2023
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology
10.1093/eurheartj/ehy596 · 2018
Role of diabetes in congestive heart failure: the Framingham study
10.1016/0002-9149(74)90089-7 · 1974
Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
10.1161/cir.0000000000000691 · 2019
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
10.1093/eurheartj/ehv134 · 2015
2026 AHA/ACC/ADA/ASN Guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1161/cir.0000000000001453 · 2026
Cardiovascular–kidney–metabolic syndrome stages, echocardiographic characteristics, and heart failure risk: the atherosclerosis risk in communities study
10.1161/circulationaha.125.077894 · 2026
Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association
10.1161/cir.0000000000001191 · 2023
Cardiovascular disease in chronic kidney disease
10.1093/eurheartj/ehaf167 · 2025
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
2024
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
10.1172/jci200319451 · 2003
Increased oxidative stress in obesity and its impact on metabolic syndrome
10.1172/jci21625 · 2004
Human epicardial adipose tissue is a source of inflammatory mediators
10.1161/01.cir.0000099542.57313.c5 · 2003
Adiponectin regulates albuminuria and podocyte function in mice
2008
Biochemistry and molecular cell biology of diabetic complications
10.1038/414813a · 2001
Oxidative stress and diabetic complications
10.1161/circresaha.110.223545 · 2010
The interplay between diabetes, cardiovascular disease, and kidney disease
10.2337/db20211-13 · 2021
The evolving concept from cardiovascular-kidney-metabolic syndrome to metabolic associated liver-cardiovascular-kidney syndrome: insights from endocrinology
10.1007/s11154-025-10013-6 · 2026
Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1159/000539371 · 2024
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
10.1136/gutjnl-2020-320622 · 2020
NAFLD as a driver of chronic kidney disease
10.1016/j.jhep.2020.01.013 · 2020
Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis
10.1007/s00330-024-10798-1 · 2024
Association of the non-alcoholic fatty liver disease fibrosis score with subclinical myocardial remodeling in patients with type 2 diabetes: a cross-sectional study in China
10.1111/jdi.13430 · 2021
Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease
10.1007/s11739-022-02966-2 · 2022
Cellular senescence, inflammaging and cardiovascular disease
10.1111/imr.70084 · 2026
Aging at the crossroads of organ interactions: implications for the heart
10.1161/circresaha.125.325637 · 2025
Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus
10.1016/j.jacc.2017.07.792 · 2017
Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus
10.1016/j.echo.2014.01.001 · 2014
Animal models for preclinical research on multifactorial human conditions: the case of cardiovascular-kidney-metabolic syndrome
10.1016/j.biopha.2025.118269 · 2025
Translation animal models of diabetic kidney disease: biochemical and histological phenotypes, advantages and limitations
10.2147/dmso.s408170 · 2023
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas
10.33549/physiolres.930111 · 2001
Impact of genetic background on nephropathy in diabetic mice
10.1152/ajprenal.00204.2005 · 2006
Both sexes develop DKD in the CD1 uninephrectomized streptozotocin mouse model
10.1038/s41598-023-42670-5 · 2023
Transforming the cardiometabolic disease landscape: multimodal AI-powered approaches in prevention and management
10.1016/j.cmet.2024.02.002 · doi-reference
Renal fat accumulation assessed by MRI or CT and its association with clinical and metabolic disorders: a systematic imaging review
10.3390/jcm14124305 · doi-reference
Total-body positron emission tomography: investigating mechanisms in cardiovascular-kidney-metabolic syndrome
10.1016/j.nuclcard.2025.102299 · doi-reference
Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study
10.1016/j.eclinm.2024.102426 · doi-reference
Disparities in SGLT2 inhibitor or glucagon-like peptide 1 receptor agonist initiation among medicare-insured adults with CKD in the United States
10.1016/j.xkme.2022.100564 · doi-reference
Integrating social determinants of health in the management of cardiovascular-kidney-metabolic syndrome
10.1161/jaha.124.036518 · doi-reference
Beyond siloed care: the promise and challenge of cardiovascular-kidney-metabolic syndrome
10.1161/circulationaha.126.080672 · doi-reference
Implementation barriers to evidence-based cardiovascular-kidney-metabolic syndrome management
10.1016/j.hlc.2025.05.095 · doi-reference
Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study: SAVE investigators
10.1016/s0735-1097(96)00489-5 · doi-reference
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
10.1016/s0140-6736(11)60739-3 · doi-reference
Effect of a multifactorial intervention on mortality in type 2 diabetes
10.1056/nejmoa0706245 · doi-reference
A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association
10.1161/cir.0000000000001186 · doi-reference
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
10.1016/s2213-8587(17)30412-6 · doi-reference
Weight can't wait: a guide to discussing obesity and organizing treatment in the primary care setting
10.1002/oby.23154 · doi-reference
Perceived judgment about weight can negatively influence weight loss: a cross-sectional study of overweight and obese patients
10.1016/j.ypmed.2014.02.001 · doi-reference
Bariatric surgery and long-term cardiovascular events
10.1001/jama.2011.1914 · doi-reference
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
10.2337/dc10-2415 · doi-reference
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
10.1093/eurheartj/ehab368 · doi-reference
2021 ESC guidelines on cardiovascular disease prevention in clinical practice
10.1093/eurheartj/ehab484 · doi-reference
Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus
10.1161/circulationaha.119.042685 · doi-reference
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
10.1056/nejmoa2110956 · doi-reference
Tirzepatide for heart failure with preserved ejection fraction and obesity
10.1056/nejmoa2410027 · doi-reference
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
10.1056/nejmoa2025845 · doi-reference
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
10.1001/jamacardio.2020.4511 · doi-reference
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · doi-reference
Impact of a multidisciplinary approach on cardiometabolic risk reduction in a multiracial cohort of adults: a 1-year pilot study
10.3390/nu14163391 · doi-reference
Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial
10.1001/jama.2023.2854 · doi-reference
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction: SOLVD (Studies of Left Ventricular Dysfunction) investigators
10.1161/01.cir.88.5.2277 · doi-reference
Evaluation, management and therapeutic approach of cardiovascular-kidney-metabolic syndrome: a multidisciplinary Delphi expert consensus
10.3390/jcm14248930 · doi-reference
2026 ESC guidelines for the management of heart failure
10.1093/eurheartj/ehag100 · doi-reference
2026 ESC guidelines for the management of cardiovascular disease and chronic kidney disease
10.1093/eurheartj/ehag098 · doi-reference
DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
10.1016/j.jdiacomp.2021.108101 · doi-reference
Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care
10.1161/circoutcomes.120.007264 · doi-reference
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)
10.2337/dci22-0027 · doi-reference
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · doi-reference
Cardiovascular, kidney, liver, and metabolic interactions in heart failure: breaking down silos
10.1161/circresaha.125.325602 · doi-reference
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
10.1056/nejmoa2403347 · doi-reference
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
10.1056/nejmoa2306963 · doi-reference
SGLT2 Inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition
10.1016/j.cmet.2020.06.020 · doi-reference